Cardiff Oncology has filed a patent for a method of treating hematological cancer. The method involves determining the presence of mutations in genes encoding a spliceosome protein in a patient’s nucleic acids and administering onvansertib and decitabine if the mutations are present, which can reduce or inhibit the progression of the cancer. GlobalData’s report on Cardiff Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Cardiff Oncology Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cardiff Oncology,personalized medicine biomarkers was a key innovation area identified from patents. Cardiff Oncology's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Method for treating hematological cancer using onvansertib and decitabine

Source: United States Patent and Trademark Office(USPTO). Credit: Cardiff Oncology Inc

A recently filed patent (Publication Number: US20230183814A1) describes a method for treating cancer by determining the presence or absence of mutations in genes encoding a spliceosome protein and administering a combination of onvansertib and decitabine to the subject. The method specifically focuses on hematological cancers, such as lymphomas and leukemias. The genes targeted in this method include SRSF2, SF3B1, ZRSR2, U2AF1, and U2AF2.

The method involves obtaining a biological sample from the subject, which can include bodily fluids, tissues, cells, or a combination thereof. The sample nucleic acids are then analyzed to determine the presence or absence of mutations in the genes encoding spliceosome proteins. If mutations are detected, the subject is administered onvansertib and decitabine to reduce or inhibit the progression of the cancer.

The combination of onvansertib and decitabine is shown to have a synergistic effect in reducing or inhibiting the progression of hematological cancer compared to using either drug alone or the additive effect of both drugs separately. The method also improves therapeutic effects, such as complete remission with complete hematological recovery, bone marrow response, and overall response rate, in the subject compared to a control or baseline.

The administration of onvansertib and decitabine can be done sequentially, with onvansertib given orally and decitabine given intravenously. The drugs can be administered in cycles of at least 7, 21, or 28 days, with at least four days of administration in each cycle. The subject may undergo multiple cycles of treatment.

The dosage of onvansertib ranges from 8 mg/m2 to 90 mg/m2, while the dosage of decitabine ranges from 10 mg/m2 to 25 mg/m2. The method is applicable to various types of hematological cancers, including lymphomas, leukemias, and myelodysplastic syndrome, and can be used for advanced, metastatic, refractory, or relapsed cases.

Additionally, the patent also describes a kit that includes onvansertib and a manual providing instructions for determining the presence or absence of mutations in genes encoding spliceosome proteins and administering onvansertib and decitabine if mutations are detected. The manual includes specific dosage instructions for onvansertib and decitabine administration.

Overall, this patent presents a method for treating hematological cancers by targeting specific mutations in genes encoding spliceosome proteins and administering a combination of onvansertib and decitabine. The method shows improved therapeutic effects and can be used for various types and stages of hematological cancer.

To know more about GlobalData’s detailed insights on Cardiff Oncology, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies